Group One Trading
TVTX icon

Group One Trading’s Travere Therapeutics TVTX Stock Holding History

Group One Trading’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Sell
39,900
-80,100
-67% -$2.39M ﹤0.01% 2552
2025
Q4 		$4.59M Buy
120,000
+63,900
+114% +$2.08M 0.01% 1582
2025
Q3 		$1.34M Sell
56,100
-195,900
-78% -$3.68M ﹤0.01% 2720
2025
Q2 		$3.73M Buy
252,000
+103,300
+69% +$1.71M 0.01% 1564
2025
Q1 		$2.66M Buy
148,700
+106,100
+249% +$2.15M 0.01% 1576
2024
Q4 		$742K Sell
42,600
-12,100
-22% -$214K ﹤0.01% 2844
2024
Q3 		$765K Buy
54,700
+16,600
+44% +$173K ﹤0.01% 2530
2024
Q2 		$313K Sell
38,100
-6,700
-15% -$45.1K ﹤0.01% 2996
2024
Q1 		$345K Sell
44,800
-67,900
-60% -$573K ﹤0.01% 3087
2023
Q4 		$1.01M Sell
112,700
-89,600
-44% -$652K ﹤0.01% 2451
2023
Q3 		$1.81M Buy
202,300
+194,400
+2,461% +$2.74M 0.01% 1720
2023
Q2 		$121K Buy
7,900
+1,800
+30% +$32.7K ﹤0.01% 4425
2023
Q1 		$137K Sell
6,100
-8,900
-59% -$189K ﹤0.01% 4012
2022
Q4 		$315K Hold
15,000
– – ﹤0.01% 3457
2022
Q3 		$370K Sell
15,000
-1,500
-9% -$38.8K ﹤0.01% 3527
2022
Q2 		$400K Buy
16,500
+500
+3% +$12.6K ﹤0.01% 3636
2022
Q1 		$412K Buy
16,000
+3,300
+26% +$87.6K ﹤0.01% 4029
2021
Q4 		$394K Buy
12,700
+8,700
+218% +$245K ﹤0.01% 4395
2021
Q3 		$97K Buy
4,000
+2,100
+111% +$38.6K ﹤0.01% 5945
2021
Q2 		$28K Buy
1,900
+1,700
+850% +$33.5K ﹤0.01% 6999
2021
Q1 		$5K Buy
+200
New +$5.53K ﹤0.01% 7251
2020
Q4 		– Sell
-10,000
Closed -$185K – 7017
2020
Q3 		$185K Buy
+10,000
New +$194K ﹤0.01% 3709
2020
Q1 		– Sell
-10,000
Closed -$142K – 5753
2019
Q4 		$142K Sell
10,000
-26,400
-73% -$337K ﹤0.01% 3408
2019
Q3 		$422K Buy
+36,400
New +$602K ﹤0.01% 2479
2019
Q2 		– Sell
-1,000
Closed -$23K – 5407
2019
Q1 		$23K Buy
+1,000
New +$22.1K ﹤0.01% 3964
2018
Q4 		– Sell
-9,700
Closed -$279K – 5429
2018
Q3 		$279K Buy
+9,700
New +$277K ﹤0.01% 2764
2018
Q1 		– Sell
-12,500
Closed -$263K – 5333
2017
Q4 		$263K Buy
12,500
+500
+4% +$11.4K ﹤0.01% 2751
2017
Q3 		$299K Buy
12,000
+10,800
+900% +$238K ﹤0.01% 2474
2017
Q2 		$23K Buy
1,200
+600
+100% +$10.9K ﹤0.01% 3901
2017
Q1 		$11K Sell
600
-16,200
-96% -$317K ﹤0.01% 4095
2016
Q4 		$318K Sell
16,800
-17,100
-50% -$350K ﹤0.01% 2080
2016
Q3 		$759K Buy
33,900
+20,700
+157% +$394K 0.01% 1481
2016
Q2 		$235K Buy
13,200
+2,000
+18% +$32.4K ﹤0.01% 2291
2016
Q1 		$153K Sell
11,200
-65,600
-85% -$995K ﹤0.01% 2513
2015
Q4 		$1.48M Sell
76,800
-6,800
-8% -$136K 0.02% 1052
2015
Q3 		$1.69M Buy
83,600
+56,400
+207% +$1.67M 0.02% 898
2015
Q2 		$902K Sell
27,200
-11,000
-29% -$301K 0.01% 1289
2015
Q1 		$915K Buy
38,200
+26,000
+213% +$396K 0.01% 1155
2014
Q4 		$149K Sell
12,200
-1,300
-10% -$13.5K ﹤0.01% 2542
2014
Q3 		$122K Sell
13,500
-4,600
-25% -$54.1K ﹤0.01% 2822
2014
Q2 		$212K Buy
+18,100
New +$245K ﹤0.01% 2354

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading's TVTX Position: Q4 2025 in Review

Group One Trading sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 15,008 shares — an estimated $488K sold.

Group One Trading first reported a position in TVTX in Q2 2014 and held it in 28 quarters. The position peaked at $1.21M in Q1 2016. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Group One Trading reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 15,008 Travere Therapeutics shares in Q4 2025, an estimated $488K.
  • Group One Trading first reported a position in Travere Therapeutics in Q2 2014 and held it in 28 quarters.
  • Group One Trading's Travere Therapeutics position peaked at $1.21M in Q1 2016.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.